Curvebeam AI Ltd. ( (AU:CVB) ) has issued an update.
CurveBeam AI Limited reported a significant increase in purchase orders for Q3 FY25, with a 40% rise compared to the previous year, and a 67% increase over the first three quarters of the fiscal year. The company is advancing its financial position by securing a non-binding term sheet for an international financing facility, which will support leasing deals in Europe and other key markets. This move is expected to enhance cash flow, with projections indicating a positive cash position by Q4 FY25. Additionally, CurveBeam AI is progressing with the validation of its enhanced HiRise™ system, aimed at integration with robotic surgical systems, which could further solidify its market position.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a developer and manufacturer of specialized medical imaging equipment, specifically point-of-care CT devices, enhanced by AI-enabled SaaS-based clinical assessment solutions. The company focuses on providing advanced imaging solutions for healthcare facilities, aiming to improve diagnostic accuracy and efficiency.
YTD Price Performance: -28.57%
Average Trading Volume: 320,295
Technical Sentiment Signal: Buy
Current Market Cap: A$39.03M
See more data about CVB stock on TipRanks’ Stock Analysis page.